Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control
posted on
Jan 27, 2023 09:55AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
My guess is that they hope for better results by dropping the androgen-deprived therapy and adding the BET Bromodomain Inhibitor ZEN-3694.
PubMed: "BET bromodomain inhibitors block prostate cancer cell growth at least in part through c-Myc and androgen receptor (AR) suppression."
Koo